Sangamo's Legacy Auctioned: A New Chapter for Genomic Medicine's Pioneer

RICHMOND, CA – August 12, 2026 – The final act for Sangamo Therapeutics as a pioneering, independent force in genomic medicine has arrived not with a breakthrough, but with the fall of a gavel. The company, operating under Chapter 11 bankruptcy protection, announced today the successful conclusion of a court-supervised auction, selling off its crown-jewel assets to pharmaceutical giants PTC Therapeutics and Eli Lilly for approximately $163.55 million in immediate cash and up to $100 million in future payments.

The sale marks a somber milestone for a company that once stood at the vanguard of gene editing, but it also signals a critical new phase for its innovations. Sangamo’s most promising technologies, once constrained by a dwindling cash runway, are now in the hands of corporations with the vast resources necessary to carry them across the finish line.

A Pioneer's Painful Restructuring

Sangamo's journey into bankruptcy is a cautionary tale about the brutal economics of biotech. As the original pioneer of zinc finger nuclease (ZFN) technology, Sangamo was editing genes years before CRISPR became a household name. Yet, despite its scientific pedigree, the company succumbed to a perfect storm of a biotech funding winter, the loss of key collaboration revenue, and a strategic pivot towards neurology that failed to generate returns quickly enough. The result was a liquidity crisis that forced it into Chapter 11 in June 2026.

The auction was framed as a necessary step to salvage value from decades of research. "Our priority has been to seek value-maximizing transactions for all stakeholders," said Sangamo CEO Sandy Macrae in today’s announcement. "We are pleased that our platform technologies, Fabry disease and prion programs attracted strong interest from parties who have the scale to continue their development for patients in need."

For industry observers, the sale is a pragmatic end to a long struggle. While Sangamo couldn't sustain the immense cost of late-stage clinical development and commercialization, the fierce bidding for its assets confirms the enduring value of its scientific contributions.

Big Pharma's Strategic Haul

The auction saw two major players walk away with significant additions to their pipelines and platforms. The competitive nature of the bidding, which dramatically inflated the final price for one key asset, reveals a calculated, long-term bet on the future of genomic medicine.

PTC Therapeutics emerged as the winning bidder for Sangamo’s late-stage Fabry disease program, isaralgagene civaparvovec (ST-920). The company will pay $111 million in cash, a figure that dwarfs the initial $25 million “stalking horse” bid placed by Astellas Pharma. This substantial increase underscores the perceived value of the gene therapy, which has shown promising data for the rare genetic disorder. PTC’s deal also includes up to $100 million in potential milestone payments tied directly to FDA approval, aligning the purchase price with regulatory success. This acquisition seamlessly fits into PTC’s established focus on rare diseases, providing it with a potential blockbuster and expanding its gene therapy portfolio.

Meanwhile, Eli Lilly executed a different kind of strategic coup. For $50 million, Lilly acquired not just a single drug program but the entire toolbox. The purchase includes Sangamo’s foundational zinc finger and MINT gene editing platforms, its advanced capsid delivery technologies, and its preclinical prion disease program. For Lilly, which has been aggressively building its capabilities in genetic medicine and neuroscience, this is a profound strategic investment. Acquiring Sangamo’s STAC-BBB technology, a platform designed to shuttle gene therapies across the formidable blood-brain barrier, is particularly significant for developing new treatments for central nervous system disorders. Lilly didn't just buy a product; it bought the engine to create a new generation of genomic medicines.

The Future of Sangamo's Dispersed Legacy

While the sales to PTC and Lilly represent a crucial step in Sangamo’s reorganization, the process is not yet complete. The deals are pending final approval by the U.S. Bankruptcy Court, with hearings expected later this quarter. The proceeds will then be distributed to satisfy obligations to creditors and stakeholders through the complex Chapter 11 process.

Sangamo continues to seek buyers for its remaining assets, including a clinical-stage program for chronic neuropathic pain (ST-503), a hemophilia A gene therapy, and its cell therapy and T-Reg assets. The successful auction of its primary programs, however, signals the effective end of Sangamo as an integrated research and development entity.

The broader implications for the genomic medicine landscape are significant. The event highlights a powerful consolidation trend where larger, well-capitalized pharmaceutical companies are absorbing the innovations of smaller biotechs that stumble on the path to commercialization. For the technologies themselves, this is not a death knell but a rebirth. Lilly's acquisition provides a powerful new champion for zinc finger technology, ensuring its continued evolution. For patients, the transfer of the Fabry and prion disease programs to companies with deep pockets and global reach offers the best hope that these potentially life-changing therapies will one day become available.

Sangamo's story is ending, but its technological legacy, now dispersed among industry giants, is just beginning a new chapter.